In addition to Smad dependent actions, TGF-β signaling also employs non-Smad effects, especially in cancer cells, such as activation of the PI3K pathway, which utilizes Akt, a proto-oncogene intermediate in the pathway[23]. This evidence concerns the gene TGFB1 and cancer.